Until recently, visible light (400-700 nm) has been regarded to have no significant cutaneous photobiologic effects . However, they contribute to ROS production and to skin damage attributed to UV light.
“We should not forget that not only UV light but also visible light contributes to the production of ROS,” said Dr Serena Lembo (University of Naples Federico II, Italy). Irradiation of human skin equivalents with visible light has been shown to induce production of ROS, proinflammatory cytokines, and matrix metalloproteinases (MMP)-1 expression in a dose dependent manner . Another trial assessed the free radical induction by sunlight in different spectral regions . It showed that although UV light stimulated the most intensive radical formation, visible light and even near infrared light also considerably contributed to the free radical formation. Half of all free radicals generated in the whole solar spectrum are induced by visible light and near infrared light . According to this trial, visible light energy is not potent enough to produce radicals directly. However, within the mitochondria and by the activity of several enzymes, ROS are produced. The effect of visible light in the extracellular matrix is very similar to UV radiation: it increases MMP-1 and MMP-9 expression and decreases type 1 procollagen levels in human skin in vivo, thus contributing to photoaging .
Visible light penetrates deep into the dermis. The erythema is considered a result of dilatation of the vasculature of the subpapillary plexus. Production of radicals also induces inflammatory processes and this chronic process might contribute to DNA damage and carcinogenesis. Although sunscreens effectively protect against UV radiation, they are not as efficient stopping visible light and infrared light. Thus, the levels of skin ROS may still overcome the natural antioxidant reservoir in the skin and cause skin damage [2,4].
Dr Lembo also mentioned a study that showed that immediate pigment darkening induced by visible light is not significantly different from that produced by UV . “In this study, visible light even induced a more potent and more long-lasting pigmentation compared with UVA1,” said Dr Lembo. Compared with UVB irradiation, the shorter wavelengths of visible light, the blue-violet light, induced a significantly more pronounced hyperpigmentation that lasted up to 3 months, but only in melano-competent individuals . These findings have potential implications due to the possible role of visible light in the pathogenesis of pigmentary disorders, such as melasma.
In another study, commercially available sunscreens were found to have minimal effects on reducing visible light-induced ROS. Results showed that MMP-1 expression following infrared radiation can be prevented by the addition of appropriate antioxidants . Thus, increasing the antioxidant threshold of the skin is a method to increase the buffering ability of the skin against ROS induced by visible light. A poster presented during the EADV 2019 meeting demonstrated that addition of the antioxidant resveratrol can also be used successfully as a photostabiliser of a chemical UVA filter in sunscreen products, thus killing two birds with one stone .
- Lembo S. D2T03.4B, EADV 2019, 9-13 Oct, Madrid, Spain.
- Liebel F, et al. J Invest Dermatol 2012;132:1902-7.
- Lohan SB, et al. Exp Dermatol 2016;25:380-5.
- Seifried HE, et al. J Nutr Biochem 2007;18:567-79.
- Cho S, et al. J Dermatol Sci 2008;50:123–133.
- Ramasubramaniam R, et al. Photobiol Sci 2011;10:1887-93.
- Duteil L, et al. Pigment Cell Melanoma Res 2014;27:822-6.
- Schroeder P, et al. J Invest Dermatol 2008;128:2491-7.
- Velasco MV, et al. P1915, EADV 2019, 9-13 Oct, Madrid, Spain.
« No hint of teratogenicity through ixekizumab Next Article
Ligelizumab for CSU: symptom control and high response rates in re-treatment »
Table of Contents: EADV 2019
Letter from the Editor
IL-17A blocker effective in paediatric psoriasis patients
Rituximab beats mycophenolate mofetil in pemphigus vulgaris
Novel JAK1/2 inhibitor shows remarkable efficacy in alopecia areata
Acne highly influenced by climate, pollutants, and unhealthy diet
JAK inhibition plus TCS lead to high clearance rates in AD
No cancer risk with long-term use of tacrolimus, a topical calcineurin inhibitor, in children with AD
Green light for a second JAK inhibitor in AD
Topical ruxolitinib effective in vitiligo
Small molecules: interesting novel treatment options in AD
IL-1⍺ blockade: a new treatment option in AD
IL-4/IL-13 blockade leads to rapid itch reduction in adolescents
How to manage conjunctivitis in AD patients treated with a biologic
Biologics: increasingly used in paediatric dermatology
Spotlight on Psoriasis
IL-17 blocker: effective and safe in patients with comorbidities
ESPRIT registry: sharp decline in mortality in patients treated with a TNF blocker
Relationship psoriasis and NAFLD: new data on the hepato-dermal axis
Novel selective IL-23 blocker equally effective in patients with metabolic syndrome
Selective IL-23 blocker crushes fumaric acids in all assessed efficacy endpoints
No hint of teratogenicity through ixekizumab
New Insights in Photoprotection
Systemic photoprotection: a valuable addition to topical sun protection
The underestimated effect of visible light
Comorbidities more common in chronic urticaria, psoriasis, and AD
D-Dimer as future biomarker in CSU management?
Ligelizumab for CSU: symptom control and high response rates in re-treatment
Rosacea – From New Spectrum to New Therapy
New guidance on rosacea therapy according to phenotype
Best of the Posters
Above-the-neck melanoma more prone to metastases
Reduced sleep quality in dermatoses influenced by itch and pain
Anxiety and depression are common in families of AD infants
Certolizumab pegol efficacious for head and neck psoriasis
Atopic dermatitis and psoriasis: on a spectrum?
Favourable safety profile of long-term use of ixekizumab